Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer

Autor: Seesaha PK, Wang KX, Wang GQ, Cui TY, Zhao FJ, Pan LL, Li XC, Shu YQ, Chen XF

Publikováno v: OncoTargets and Therapy, Vol Volume 14, Pp 1873-1882 (2021)

Poshita-Kumari Seesaha,1,* Kang-Xin Wang,2,* Guo-Qun Wang,2 Ting-Yun Cui,2 Feng-Jiao Zhao,1 Lan-Lan Pan,1 Xiang-Cheng Li,3 Yong-Qian Shu,1 Xiao-Feng Chen1,2 1Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanji

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doajarticles::55f4bc668b6315f735489b76659ba2fb
https://www.dovepress.com/current-progress-and-future-perspectives-of-immune-checkpoint-inhibito-peer-reviewed-article-OTT

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.

Autor: Chen X; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Department of Oncology, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China., Wu X; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Wu H; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Gu Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Shao Y; Medical Department, Nanjing Geneseeq Technology Inc, Nanjing, China., Shao Q; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Zhu F; Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Li X; Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Qian X; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Hu J; Department of Oncology, Nanjing Red Cross Hospital, Nanjing, China., Zhao F; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Mao W; Department of Oncology, Jiangyin People's Hospital, Jiangyin, China., Sun J; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Wang J; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Han G; Department of Oncology, Taizhou People's Hospital Affiliated to Nantong University, Taizhou, China., Li C; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Xia Y; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Seesaha PK; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Zhu D; Medical Department, Nanjing Geneseeq Technology Inc, Nanjing, China., Li H; Medical Department, Jiangsu Hengrui Medicine Co Ltd, Lianyungang, China., Zhang J; Medical Department, 3D Medicines Inc, Shanghai, China., Wang G; Medical Department, Burning Rock Biotech, Guangzhou, China., Wang X; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Li X; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Shu Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China shuyongqian@csco.org.cn.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Nov; Vol. 8 (2).

The interplay between dietary factors, gut microbiome and colorectal cancer: a new era of colorectal cancer prevention.

Autor: Seesaha PK; Oncology Department, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, PR China., Chen X; Oncology Department, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, PR China., Wu X; Hepatobiliary Center, The First Affiliated Hospital, Nanjing Medical University, Jiangsu, PR China., Xu H; Department of Nutrition, Third Military Medical University Daping Hospital & Research Institute of Surgery, Chongqing 400042, Sichuan, PR China., Li C; Hepatobiliary Center, The First Affiliated Hospital, Nanjing Medical University, Jiangsu, PR China., Jheengut Y; Oncology Department, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, PR China., Zhao F; Oncology Department, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, PR China., Liu L; School of Public Health, Guizhou Medical University, Guiyang, PR China., Zhang D; Department of General Surgery, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, PR China.

Publikováno v: Future oncology (London, England) [Future Oncol] 2020 Mar; Vol. 16 (7), pp. 293-306. Date of Electronic Publication: 2020 Feb 18.

Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer.

Autor: Caixia Li, Wenlei Ye, Wenni Zhou, ,Zhikang Ye, Weihong Yang, Zhongping Cheng

Publikováno v: Frontiers in Oncology; 12/12/2022, Vol. 12, p1-5, 5p

Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report.

Autor: Fengjiao Zhao, Yong Zhou, Kumari Seesaha, Poshita, Yihong Zhang, Siqin Liu, Xiaoyan Gan, Jun Hu, Yanhong Gu, Xiaofeng Chen, Zhao, Fengjiao, Zhou, Yong, Seesaha, Poshita Kumari, Zhang, Yihong, Liu, Siqin, Gan, Xiaoyan, Hu, Jun, Gu, Yanhong, Chen, Xiaofeng

Publikováno v: Medicine; 9/18/2020, Vol. 99 Issue 38, p1-4, 4p